MMP-Activated Liposomal Nanoplatform Co-loaded with Kaempferol and ICG for Targeted Imaging and Therapy of Abdominal Aortic Aneurysm

Read full text Summarise with VIRAT
Authors: Anqi Chen, Zhengan Huang, Wei Zeng, Yanxia Liang, Guanxi Wen, Jiayu Ye, Yanbin Guo, Jiayi Xu, Yingying Liu, Hongwen Fei
Cited by: 0
References: 61

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disorder characterized by excessive oxidative stress, chronic inflammation, and extracellular matrix (ECM) degradation. Despite its high prevalence and poor clinical outcomes, no effective pharmacological therapies currently exist. Here, we developed a theranostic liposomal nanoplatform co-loaded with kaempferol (KPF), a natural flavonoid with potent anti-inflammatory and antioxidant activity, and indocyanine green (ICG), a photoacoustic imaging agent. The platform was surface-modified with an activatable cell-penetrating peptide (ACPP), a protease-cleavable cell-penetrating peptide that becomes active upon exposure to MMP-9 in AAA lesions, thereby enabling targeted delivery. The resulting formulation (ICG-KPF@ALNPs) exhibited selective accumulation in aneurysmal tissues and produced strong photoacoustic signals in vitro and in vivo. Therapeutically, ICG-KPF@ALNPs markedly reduced reactive oxygen species (ROS), suppressed inflammatory cytokines, and preserved ECM integrity. Mechanistically, kaempferol exerted a dual protective effect by activating the Nrf2/HO-1 pathway to scavenge ROS and inhibiting the NLRP3 inflammasome to limit macrophage pyroptosis, collectively mitigating oxidative stress and inflammation. These findings highlight ICG-KPF@ALNPs as a promising nanotheranostic strategy for noninvasive imaging and targeted treatment of AAA.

Fields of Study & Subjects

Aortic aneurysm repair treatments Nanoparticle-Based Drug Delivery Nanoplatforms for cancer theranostics

Publication details

Journal / source
ACS Applied Materials & Interfaces
Volume
18
Issue
13
Pages
18793–18808
Publication date
27 March 2026
Language
EN